Is Chromadex Corp. overvalued or undervalued?

As of 6 August 2025, the valuation grade for Chromadex Corp. has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 63, a Price to Book Value of 18.43, and an EV to EBITDA ratio of 58.09, all of which are significantly higher than industry norms, suggesting that investors are paying a premium for its shares.
In comparison to its peers, Chromadex Corp. has a higher P/E ratio than USANA Health Sciences, which stands at 16.23, and LifeVantage Corp., which has a P/E of 14.81, further reinforcing its expensive valuation status. Despite impressive recent returns, such as a 185.63% increase over the past year compared to the S&P 500's 17.14%, the elevated valuation metrics indicate that the stock may not be justified at its current price level.